Presentation and effectiveness of early treatment of type 2 diabetes in youth: Lessons from the TODAY study

for the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Study Group

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Objective: The objectives were to (i) describe the characteristics of a large ethnically/racially and geographically diverse population of adolescents with recent-onset type 2 diabetes (T2D), and (ii) assess the effects of short-term diabetes education and treatment with metformin on clinical and biochemical parameters in this cohort. Research design and methods: Descriptive characteristics were determined for subjects screened for Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) who met criteria for diagnosis of T2D (n=1092). Changes in clinical and biochemical parameters were determined for those who completed at least 8wk of the run-in phase of the trial, which included standardized diabetes education and treatment with metformin. Further analysis determined whether these changes differed according to the treatment at screening. Main outcome measures: Demographic, biochemical measurements, and anthropometrics at screening and changes over 8wk of run-in were the outcome measures. Results: Subjects screened for TODAY had a median age of 14yr and median hemoglobin A1c (HbA1c) of 6.9% (52mM/M), 2/3 were female, and ethnic/racial minorities were overrepresented. Dyslipidemia and hypertension were common comorbidities. During run-in, HbA1c, body mass index, low-density lipoprotein cholesterol, triglycerides, and blood pressure significantly improved. Nearly all participants on insulin therapy at screening were able to attain target HbA1c following insulin discontinuation. Conclusions: Treatment with metformin and diabetes education provided short-term improvements in glycemic control and cardiometabolic risk factors in a large adolescent T2D cohort. Nearly all insulin-treated youth could be successfully weaned off insulin with continued improvement in glycemic control.

Original languageEnglish (US)
Pages (from-to)212-221
Number of pages10
JournalPediatric Diabetes
Volume17
Issue number3
DOIs
StatePublished - May 1 2016
Externally publishedYes

Fingerprint

Type 2 Diabetes Mellitus
Metformin
Insulin
Hemoglobins
Education
Therapeutics
Outcome Assessment (Health Care)
Dyslipidemias
LDL Cholesterol
Comorbidity
Body Mass Index
Research Design
Demography
Blood Pressure
Hypertension
Population

Keywords

  • Diabetes education
  • Insulin therapy
  • Metformin

ASJC Scopus subject areas

  • Internal Medicine
  • Pediatrics, Perinatology, and Child Health
  • Endocrinology, Diabetes and Metabolism

Cite this

for the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Study Group (2016). Presentation and effectiveness of early treatment of type 2 diabetes in youth: Lessons from the TODAY study. Pediatric Diabetes, 17(3), 212-221. https://doi.org/10.1111/pedi.12264

Presentation and effectiveness of early treatment of type 2 diabetes in youth : Lessons from the TODAY study. / for the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Study Group.

In: Pediatric Diabetes, Vol. 17, No. 3, 01.05.2016, p. 212-221.

Research output: Contribution to journalArticle

for the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Study Group 2016, 'Presentation and effectiveness of early treatment of type 2 diabetes in youth: Lessons from the TODAY study', Pediatric Diabetes, vol. 17, no. 3, pp. 212-221. https://doi.org/10.1111/pedi.12264
for the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Study Group. Presentation and effectiveness of early treatment of type 2 diabetes in youth: Lessons from the TODAY study. Pediatric Diabetes. 2016 May 1;17(3):212-221. https://doi.org/10.1111/pedi.12264
for the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Study Group. / Presentation and effectiveness of early treatment of type 2 diabetes in youth : Lessons from the TODAY study. In: Pediatric Diabetes. 2016 ; Vol. 17, No. 3. pp. 212-221.
@article{eda3381c56244049832fed726b8b3a90,
title = "Presentation and effectiveness of early treatment of type 2 diabetes in youth: Lessons from the TODAY study",
abstract = "Objective: The objectives were to (i) describe the characteristics of a large ethnically/racially and geographically diverse population of adolescents with recent-onset type 2 diabetes (T2D), and (ii) assess the effects of short-term diabetes education and treatment with metformin on clinical and biochemical parameters in this cohort. Research design and methods: Descriptive characteristics were determined for subjects screened for Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) who met criteria for diagnosis of T2D (n=1092). Changes in clinical and biochemical parameters were determined for those who completed at least 8wk of the run-in phase of the trial, which included standardized diabetes education and treatment with metformin. Further analysis determined whether these changes differed according to the treatment at screening. Main outcome measures: Demographic, biochemical measurements, and anthropometrics at screening and changes over 8wk of run-in were the outcome measures. Results: Subjects screened for TODAY had a median age of 14yr and median hemoglobin A1c (HbA1c) of 6.9{\%} (52mM/M), 2/3 were female, and ethnic/racial minorities were overrepresented. Dyslipidemia and hypertension were common comorbidities. During run-in, HbA1c, body mass index, low-density lipoprotein cholesterol, triglycerides, and blood pressure significantly improved. Nearly all participants on insulin therapy at screening were able to attain target HbA1c following insulin discontinuation. Conclusions: Treatment with metformin and diabetes education provided short-term improvements in glycemic control and cardiometabolic risk factors in a large adolescent T2D cohort. Nearly all insulin-treated youth could be successfully weaned off insulin with continued improvement in glycemic control.",
keywords = "Diabetes education, Insulin therapy, Metformin",
author = "{for the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Study Group} and Kelsey, {Megan M.} and Geffner, {Mitchell E.} and Cynthia Guandalini and Laura Pyle and Tamborlane, {William V.} and Zeitler, {Philip S.} and White, {Neil H.} and S. McKay and B. Anderson and C. Bush and S. Gunn and M. Haymond and H. Holden and K. Hwu and Jones, {S. M.} and S. McGirk and B. Schreiner and S. Thamotharan and M. Zarate and L. Cuttler and E. Abrams and T. Casey and W. Dahms and A. Davis and A. Haider and S. Huestis and C. Ievers-Landis and B. Kaminski and M. Koontz and S. MacLeish and P. McGuigan and S. Narasimhan and D. Rogers and M. Geffner and V. Barraza and N. Chang and B. Conrad and D. Dreimane and S. Estrada and L. Fisher and E. Fleury-Milfort and S. Hernandez and B. Hollen and F. Kaufman and E. Law and V. Mansilla and D. Miller and C. Mu{\~n}oz and R. Ortiz and Sanchez, {Janine E}",
year = "2016",
month = "5",
day = "1",
doi = "10.1111/pedi.12264",
language = "English (US)",
volume = "17",
pages = "212--221",
journal = "Pediatric Diabetes",
issn = "1399-543X",
publisher = "Blackwell Munksgaard",
number = "3",

}

TY - JOUR

T1 - Presentation and effectiveness of early treatment of type 2 diabetes in youth

T2 - Lessons from the TODAY study

AU - for the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Study Group

AU - Kelsey, Megan M.

AU - Geffner, Mitchell E.

AU - Guandalini, Cynthia

AU - Pyle, Laura

AU - Tamborlane, William V.

AU - Zeitler, Philip S.

AU - White, Neil H.

AU - McKay, S.

AU - Anderson, B.

AU - Bush, C.

AU - Gunn, S.

AU - Haymond, M.

AU - Holden, H.

AU - Hwu, K.

AU - Jones, S. M.

AU - McGirk, S.

AU - Schreiner, B.

AU - Thamotharan, S.

AU - Zarate, M.

AU - Cuttler, L.

AU - Abrams, E.

AU - Casey, T.

AU - Dahms, W.

AU - Davis, A.

AU - Haider, A.

AU - Huestis, S.

AU - Ievers-Landis, C.

AU - Kaminski, B.

AU - Koontz, M.

AU - MacLeish, S.

AU - McGuigan, P.

AU - Narasimhan, S.

AU - Rogers, D.

AU - Geffner, M.

AU - Barraza, V.

AU - Chang, N.

AU - Conrad, B.

AU - Dreimane, D.

AU - Estrada, S.

AU - Fisher, L.

AU - Fleury-Milfort, E.

AU - Hernandez, S.

AU - Hollen, B.

AU - Kaufman, F.

AU - Law, E.

AU - Mansilla, V.

AU - Miller, D.

AU - Muñoz, C.

AU - Ortiz, R.

AU - Sanchez, Janine E

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Objective: The objectives were to (i) describe the characteristics of a large ethnically/racially and geographically diverse population of adolescents with recent-onset type 2 diabetes (T2D), and (ii) assess the effects of short-term diabetes education and treatment with metformin on clinical and biochemical parameters in this cohort. Research design and methods: Descriptive characteristics were determined for subjects screened for Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) who met criteria for diagnosis of T2D (n=1092). Changes in clinical and biochemical parameters were determined for those who completed at least 8wk of the run-in phase of the trial, which included standardized diabetes education and treatment with metformin. Further analysis determined whether these changes differed according to the treatment at screening. Main outcome measures: Demographic, biochemical measurements, and anthropometrics at screening and changes over 8wk of run-in were the outcome measures. Results: Subjects screened for TODAY had a median age of 14yr and median hemoglobin A1c (HbA1c) of 6.9% (52mM/M), 2/3 were female, and ethnic/racial minorities were overrepresented. Dyslipidemia and hypertension were common comorbidities. During run-in, HbA1c, body mass index, low-density lipoprotein cholesterol, triglycerides, and blood pressure significantly improved. Nearly all participants on insulin therapy at screening were able to attain target HbA1c following insulin discontinuation. Conclusions: Treatment with metformin and diabetes education provided short-term improvements in glycemic control and cardiometabolic risk factors in a large adolescent T2D cohort. Nearly all insulin-treated youth could be successfully weaned off insulin with continued improvement in glycemic control.

AB - Objective: The objectives were to (i) describe the characteristics of a large ethnically/racially and geographically diverse population of adolescents with recent-onset type 2 diabetes (T2D), and (ii) assess the effects of short-term diabetes education and treatment with metformin on clinical and biochemical parameters in this cohort. Research design and methods: Descriptive characteristics were determined for subjects screened for Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) who met criteria for diagnosis of T2D (n=1092). Changes in clinical and biochemical parameters were determined for those who completed at least 8wk of the run-in phase of the trial, which included standardized diabetes education and treatment with metformin. Further analysis determined whether these changes differed according to the treatment at screening. Main outcome measures: Demographic, biochemical measurements, and anthropometrics at screening and changes over 8wk of run-in were the outcome measures. Results: Subjects screened for TODAY had a median age of 14yr and median hemoglobin A1c (HbA1c) of 6.9% (52mM/M), 2/3 were female, and ethnic/racial minorities were overrepresented. Dyslipidemia and hypertension were common comorbidities. During run-in, HbA1c, body mass index, low-density lipoprotein cholesterol, triglycerides, and blood pressure significantly improved. Nearly all participants on insulin therapy at screening were able to attain target HbA1c following insulin discontinuation. Conclusions: Treatment with metformin and diabetes education provided short-term improvements in glycemic control and cardiometabolic risk factors in a large adolescent T2D cohort. Nearly all insulin-treated youth could be successfully weaned off insulin with continued improvement in glycemic control.

KW - Diabetes education

KW - Insulin therapy

KW - Metformin

UR - http://www.scopus.com/inward/record.url?scp=84923495938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923495938&partnerID=8YFLogxK

U2 - 10.1111/pedi.12264

DO - 10.1111/pedi.12264

M3 - Article

C2 - 25690268

AN - SCOPUS:84923495938

VL - 17

SP - 212

EP - 221

JO - Pediatric Diabetes

JF - Pediatric Diabetes

SN - 1399-543X

IS - 3

ER -